Market Overview - The biopharmaceutical sector experienced a decline of 1.58% on October 14, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Iwo Biotech (300357) with a closing price of 30.21, up 4.79% on a trading volume of 149,900 shares and a turnover of 448 million yuan [1] - Kain Technology (688687) closed at 28.91, up 4.14% with a trading volume of 127,000 shares and a turnover of 369 million yuan [1] - Major decliners included: - Aopumai (688293) which closed at 56.09, down 7.20% with a trading volume of 18,200 shares and a turnover of 106 million yuan [2] - Olin Biotech (688319) closed at 23.95, down 7.06% with a trading volume of 65,500 shares and a turnover of 162 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 503 million yuan from institutional investors, while retail investors contributed a net inflow of 329 million yuan [2] - The capital flow for specific stocks showed: - Iwo Biotech (300357) had a net outflow of 43.35 million yuan from institutional investors [3] - Kain Technology (688687) experienced a net inflow of 8.78 million yuan from institutional investors [3]

Core Insights - Aopu Mai (688293) has seen a net financing increase of 213.77 million yuan on October 13, with a total financing balance of 6524.37 million yuan, marking a continuous net buying trend over the past three trading days, totaling 520.09 million yuan [1][2][3] Financing Activity Summary - On October 13, the net financing buy was 213.77 million yuan, with a financing balance of 6524.37 million yuan, representing 0.95% of the circulating market value [2] - Over the last 20 trading days, there have been 13 days of net financing purchases, indicating strong investor interest [1] - The financing balance increased by 3.39% compared to the previous day, reflecting positive market sentiment [3]

Core Insights - On October 10, Aopumai's stock fell by 1.33% with a trading volume of 96.89 million yuan [1] - As of October 10, Aopumai's financing balance totaled 63.11 million yuan, accounting for 0.91% of its market capitalization, indicating a low financing level compared to the past year [1] - For the first half of 2025, Aopumai reported a revenue of 178 million yuan, a year-on-year increase of 23.77%, and a net profit of 37.55 million yuan, up 55.55% year-on-year [2] Financing and Margin Trading - On October 10, Aopumai had a financing buy-in of 10.31 million yuan and a net financing buy of 2.56 million yuan [1] - The company had no short selling activity on October 10, with a short selling balance of 0.00 shares, indicating a high level of short selling compared to the past year [1] Shareholder and Institutional Holdings - As of June 30, 2025, Aopumai had 3,212 shareholders, an increase of 6.11% from the previous period, with an average of 24,100 circulating shares per shareholder, down 5.76% [2] - Aopumai has distributed a total of 173 million yuan in dividends since its A-share listing [3] - Among the top ten circulating shareholders, ICBC Frontier Medical Stock A increased its holdings by 1.25 million shares, while HSBC Jintrust Longteng Mixed A exited the top ten list [3]

Core Points - Shanghai Aopumai Biotechnology Co., Ltd. announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd., successfully passed the EU Qualified Person (QP) audit, receiving a compliance audit report [1][2] - The audit covered various aspects including quality management, production management, facilities, material systems, and packaging and labeling systems, confirming that Silun Biotechnology meets current EU GMP requirements [1] - This achievement establishes a solid foundation for the company's high-quality research and production services in the large molecule biopharmaceutical sector, facilitating further expansion into EU and international markets [2] Company Impact - The successful QP audit indicates that the quality management system of Silun Biotechnology has reached the standards required by EU GMP regulations [2] - The company has developed a comprehensive CDMO service platform for large molecule biopharmaceuticals, providing full-process support from early research to commercial production [1] - The passing of the QP audit is not expected to have a significant impact on the company's current performance [2]

Core Viewpoint - Aopu Mai (688293.SH) announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd. (referred to as "Silun Biotechnology"), successfully passed the Qualified Person (QP) audit by the European Union, receiving a compliance audit report [1] Group 1 - The successful completion of the QP audit indicates that Silun Biotechnology's quality management system meets the EU GMP regulatory requirements [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] - The compliance lays a solid foundation for the company to further expand into international markets, including the EU [1]

近日，上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"） 全资子公司上海思伦生物科技有限公司（以下简称"思伦生物"）顺利通过欧盟 质量授权人（QP，Qualified Person）审计，正式获得QP签发的符合性审计报告。 现就相关情况公告如下： 一、欧盟QP审计报告内容 证券代码：688293 证券简称：奥浦迈 公告编号：2025-089 上海奥浦迈生物科技股份有限公司 关于自愿披露全资子公司通过欧盟 QP 审计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次顺利通过QP审计，标志着思伦生物质量管理体系已达到欧盟GMP法规 要求，充分保证公司在大分子生物药领域的高品质研发生产服务，为进一步拓展 欧盟等国际市场奠定了坚实的基础。 本次通过欧盟QP审计不会对公司当前业绩产生较大影响，敬请广大投资者 理性投资，注意投资风险。 特此公告。 上海奥浦迈生物科技股份有限公司董事会 2025 年 9 月 27 日 依据EudraLex Volume 4（欧盟药品GMP 法规）及PIC/S 相关指导原则，此 次审 ...

Core Viewpoint - Aopu Mai (688293.SH) announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd. (referred to as "Silun Biotechnology"), successfully passed the EU Qualified Person (QP) audit, receiving a compliance audit report issued by the QP [1] Group 1 - The successful completion of the QP audit indicates that Silun Biotechnology's quality management system meets the EU GMP regulatory requirements [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] - The accomplishment lays a solid foundation for the company to further expand into international markets, including the EU [1]

Core Viewpoint - The company, Aopumai (688293.SH), announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd. (referred to as "Silun Biotechnology"), successfully passed the Qualified Person (QP) audit by the European Union, receiving a compliance audit report [1] Group 1 - The successful completion of the QP audit indicates that Silun Biotechnology's quality management system meets the EU GMP regulatory requirements [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] - The compliance lays a solid foundation for the company to further expand into international markets, including the EU [1]

格隆汇9月26日｜奥浦迈(688293.SH)公告称，公司全资子公司思伦生物近日顺利通过欧盟质量授权人 （QP）审计，正式获得QP签发的符合性审计报告。此次审计范围涵盖质量管理、生产管理、厂房设备 设施、物料系统、包装与标签系统等方面，关键环节均进行了细致审查。QP审计报告显示，思伦生物 已建立了基本的组织架构、人员配置、设施、程序等，符合当前欧盟GMP要求。本次通过欧盟QP审计 不会对公司当前业绩产生较大影响。 ...

Core Viewpoint - Aopu Mai (688293.SH) has successfully passed the Qualified Person (QP) audit conducted by its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd, marking a significant achievement in meeting EU GMP regulatory requirements [1] Group 1: Company Achievements - The successful QP audit indicates that Silun Biotechnology's quality management system meets the standards set by EU GMP regulations [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] Group 2: Market Implications - The compliance with EU standards lays a solid foundation for the company to expand into international markets, including the EU [1]